ImmunityBio raises $80M equity; Q2 revenue $26.4M (+60% QoQ), ANKTIVA units up 246%

ImmunityBio, Inc.

Registered direct offering of 29.6M shares and warrants at $2.70/unit, gross proceeds ~$80M.
Q2 2025 revenue $26.4M, up 60% from Q1 2025; year-to-date sales ~$43M.
Cash and equivalents $153.7M as of June 30, 2025.
FDA refused to file supplemental BLA for papillary NMIBC; company re-evaluating approach with new data.
UK MHRA approved ANKTIVA marketing authorization; NSCLC RCT initiated in US.

item 1.01 item 2.02 item 7.01 item 8.01 item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.